(Date:12/3/2009)...els that repels grime and dirt? Expanded battery s...el Aviv University research, just published in Na...sembling peptides at the nano-scale level that cou... a few years. , Operating in the range of 100 na...en smaller, graduate student Lihi Adler-Abramovich...
(Date:12/3/2009)...nality change in warmer water, according to an int...ay make some species more aggressive. , Experime...lia,s Great Barrier Reef have shown for the first ...imid, or consistently bold, and that these individ...eratures rise. , A slight lift of just one or tw...
(Date:12/3/2009)...m the U.S. Department of Energy,s (DOE) Brookhaven...Indian Institute of Science has made a major step ...information in DNA that is necessary to carry out ...ished in the December 1, 2009 edition of Nature S... proteins responsible for interacting at specific ...
Breaking Biology News(10 mins):A window that washes itself? 2Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 1Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 2maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 54299 1maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 54299 2maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 54299 3Members of Over 71 Million U S Households Ignored by Universal Healthcare 54296 1Members of Over 71 Million U S Households Ignored by Universal Healthcare 54296 2Members of Over 71 Million U S Households Ignored by Universal Healthcare 54296 3Members of Over 71 Million U S Households Ignored by Universal Healthcare 54296 4(Date:12/2/2009)...2 Reportlinker.com announces that ...atalogue: ,, Drug Discovery Technologies - A G... ,, http://www.reportlinker.com/p0164246/Drug-...-Trends--Opportunities.html ,, Drug discovery ...y pharmaceutical company,s business strategy. Ther...
(Date:12/2/2009)...c. 2 Peregrine Pharmaceu...etion of patient enrollment in a dose confirmation...ith relapsed glioblastoma multiforme (GBM), the de...d monoclonal antibody linked to a radioisotope bei... Cotara specifically targets cells at the center ...
(Date:12/2/2009)...therlands, December 2 Pepscan Hold...y focusing on protein mimicking,technology for the... that it,has appointed Wim E.M. Mol, Ph.D. as new ...e responsible for all of Pepscans corporate functi...tion of the company. He brings to,Pepscan more tha...
(Date:12/2/2009)... 2 S*BIO Pte Ltd today announced d..., SB1518, at The American Society of Hematology 51..., Data will be presented on the clinical result... detailing its safety, tolerability and pharmacoki...ls ranging from 100 to 600 mg. These doses were ad...
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5...evelopment, Biomarker Identification ..., Oct. 10 MultiCell,Technologies, Inc. (OTC Bulle...ve license and technology purchase agreement with ... Company,s Fa2N-4 immortalized,adult human liver c...and has agreed to purchase,certain inventory and e...
...herapeutics Corporation (Nasdaq: TARG ) today ann...of 5,750,000 shares of its common stock at a price...res are being offered by,Targanta. Targanta has gr...ase up to an additional 862,500 shares of common s...ing discounts and commissions, to cover,over-allot...
...efits of Unsaturated Fatty Acids in ... 10 Amarin Corporation plc,(NASDAQ: AMRN ) today...development strategy to capitalize on the known th...ardiovascular disease. Amarin plans to utilize,its...e to develop a series,of products targeting the va...
Other Biology Technology:MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3Targanta Therapeutics Announces Pricing of its Initial Public Offering 2Amarin Announces Initiation of Cardiovascular Development Strategy 2Amarin Announces Initiation of Cardiovascular Development Strategy 3Amarin Announces Initiation of Cardiovascular Development Strategy 4Amarin Announces Initiation of Cardiovascular Development Strategy 5Chaps Cell Extract Buffer (10X) from Cell Signaling Technology
UltraClean Microbial DNA Isolation Kit from Mo Bio Laboratories, Inc.
Custom Oligo Assay Single Locus 1920 samples from Illumina
Anti-Human L-Ficolin Monoclonal Antibody, Unconjugated, Clone GN4 from Cell Sciences
Biology Products: